Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Children's Oncology Group
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Children's Oncology Group
ClinicalTrials.gov Identifier:
NCT00899990
First received: May 9, 2009
Last updated: August 26, 2014
Last verified: August 2014

May 9, 2009
August 26, 2014
February 2008
January 2100   (final data collection date for primary outcome measure)
Banking of biological specimens, including associated demographic and clinical data [ Time Frame: Not Provided ] [ Designated as safety issue: No ]
Banking of biological specimens, including associated demographic and clinical data [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00899990 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
A COG Study for Collecting and Banking Ewing Sarcoma Specimens

This research study is collecting and storing samples of tumor tissue, bone marrow, and blood from patients with Ewing sarcoma. Collecting and storing samples of tumor tissue, bone marrow, and blood from patients with cancer to test in the laboratory may help the study of cancer in the future.

OBJECTIVES:

I. Collect biological specimens, including associated demographic and clinical data, from patients with Ewing sarcoma.

II. Provide a repository for long-term storage of Ewing sarcoma-related biological materials.

III. Make collected specimens available to qualified researchers to understand the biology of Ewing sarcoma and correlate these results with demographic and clinical data.

OUTLINE: This is a multicenter study.

Patients undergo collection of tumor specimens, bone marrow, and peripheral blood at diagnosis. Associated demographic and clinical data are collected and archived. Patients who are not enrolled on a therapeutic clinical trial are followed annually.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

tumor specimens, bone marrow and peripheral blood

Non-Probability Sample

Patients with a diagnosis of Ewing sarcoma.

  • Askin Tumor
  • Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
  • Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
  • Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Other: laboratory biomarker analysis
Correlative studies
Ancillary-Correlative (biomarker sampling)
Patients undergo collection of tumor specimens, bone marrow, and peripheral blood at diagnosis. Associated demographic and clinical data are collected and archived. Patients who are not enrolled on a therapeutic clinical trial are followed annually.
Intervention: Other: laboratory biomarker analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
700
Not Provided
January 2100   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of Ewing sarcoma, including peripheral primitive neuroectodermal tumor and Askin tumor

    • Newly diagnosed or recurrent disease
Both
up to 21 Years
No
United States,   Australia,   Canada,   New Zealand,   Puerto Rico,   Switzerland
 
NCT00899990
AEWS07B1, NCI-2009-00370, COG-AEWS07B1, CDR0000544202, AEWS07B1, AEWS07B1, U10CA098543
Yes
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Stephen Lessnick, MD, PhD Children's Oncology Group
Children's Oncology Group
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP